Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: A randomized, investigator-blind comparison

Journal of the American Academy of Dermatology

Volumn 53, Issue 4, 2005, Pages 602-609

  Draelos, Zoe ^a,b   Nayak, Anjuli ^b   Pariser, David ^c   Shupack, Jerome L ^d   Chon, Katie ^e   Abrams, Beatrice ^e   Paul, Carle F ^e  

^a DERMATOLOGY CONSULTING SERVICES   (United States)

^b Sneeze Wheeze and Itch Associate LLC ^*  (United States)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; PIMECROLIMUS; TACROLIMUS;

ADULT; AREA UNDER THE CURVE; ARTICLE; ATOPIC DERMATITIS; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; ERYTHEMA; FACE; FEMALE; HUMAN; MALE; MEDICAL ASSESSMENT; MULTICENTER STUDY; NECK; POPULATION RESEARCH; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SKIN BURNING SENSATION; SKIN IRRITATION; TREATMENT OUTCOME;

ADULT; AREA UNDER CURVE; CALCINEURIN; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; TACROLIMUS;

EID: 25844507194     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2005.06.013     Document Type: Article

References (23)

1. L.A. Bernard, and L.F. Eichenfield Topical immunomodulators for atopic dermatitis Curr Opin Pediatr 14 2002 414 418
2. J. Harper, A. Green, G. Scott, E. Gruendl, B. Dorobek, and M. Cardno First experience of topical SDZ ASM 981 in children with atopic dermatitis Br J Dermatol 144 2001 781 787
3. B.R. Allen, M. Lakhanpaul, A. Morris, S. Lateo, T. Davies, and G. Scott Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients Arch Dis Child 88 2003 969 973
4. E.J. Van Leent, M.E. Ebelin, P. Burtin, B. Dorobek, P.I. Spuls, and J.D. Bos Low systemic exposure after repeated topical application of pimecrolimus (Elidel, SD Z ASM 981) in patients with atopic dermatitis Dermatology 204 2002 63 68
5. N.A. Soter, A.B. Fleischer Jr., G.F. Webster, E. Monroe, and I. Lawrence Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety J Am Acad Dermatol 44 Suppl 2001 S39 S46
6. S. Alaiti, S. Kang, V.C. Fiedler, C.N. Ellis, D.V. Spurlin, and D. Fader Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children J Am Acad Dermatol 38 1998 69 76
7. M. Boguniewicz, V.C. Fiedler, S. Raimer, I.D. Lawrence, D.Y. Leung, and J.M. Hanifin A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children: pediatric tacrolimus study group J Allergy Clin Immunol 102 1998 637 644
8. N. Barbier, C. Paul, T. Luger, R. Allen, Y. De Prost, and K. Papp Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials program Br J Dermatol 150 2004 96 102
9. A. Allen, E. Siegfried, R. Silverman, M.L. Williams, P.M. Elias, and S.K. Szabo Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome Arch Dermatol 137 2001 747 750
10. D.M. Allen, and N.B. Esterly Significant systemic absorption of tacrolimus after topical application in a patient with lamellar ichthyosis Arch Dermatol 138 2002 1259 1260
11. D.Y. Leung, J.M. Hanifin, E.N. Charlesworth, J.T. Li, I.L. Bernstein, and W.E. Berger Disease management of atopic dermatitis: a practice parameter. Joint task force on practice parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. Work group on atopic dermatitis Ann Allergy Asthma Immunol 79 1997 197 211
12. J.M. Hanifin, and S.J. Tofte Update on therapy of atopic dermatitis J Allergy Clin Immunol 104 Suppl 1999 S123 S125
13. D. Abeck, and K. Strom Optimal management of atopic dermatitis Am J Clin Dermatol 1 2000 41 46
14. C.J. Hill, and A. Rostenberg Jr. Adverse effects from topical steroids Cutis 21 1978 624 628
15. G. Stoppoloni, F. Prisco, R. Santinelli, G. Sicuranza, and C. Giordano Potential hazards of topical steroid therapy Am J Dis Child 137 1983 1130 1131
16. S. Lewis-Jones Atopic dermatitis in childhood Hosp Med 62 2001 136 143
17. C. Queille, R. Pommarede, and J.H. Saurat Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of childhood Pediatr Dermatol 1 1984 246 253
18. M. Turpeinen Influence of age and severity of dermatitis on the percutaneous absorption of hydrocortisone in children Br J Dermatol 118 1988 517 522
19. M. Turpeinen, O.P. Salo, and S. Leisti Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease Br J Dermatol 115 1986 475 484
20. A. Stuetz, M. Grassberger, and J.G. Meingassner Pimecrolimus (Elidel, SDZ ASM 981) - preclinical pharmacologic profile and skin selectivity Semin Cutan Med Surg 20 2001 233 241
21. A. Billich, H. Aschauer, A. Aszodi, and A. Stuetz Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus Int J Pharm 269 2004 29 35
22. R.P. Kershner, and W.E. Fitzsimmons Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation Transplantation 62 1996 920 926
23. G. Scott, S.A. Osborne, G. Greig, S. Hartmann, M.E. Ebelin, and P. Burtin Pharmacokinetics of pimecrolimus, a novel nonsteroid anti-inflammatory drug, after single and multiple oral administration Clin Pharmacokinet 42 2003 1305 1314